BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 31395608)

  • 21. Wedelolactone disrupts the interaction of EZH2-EED complex and inhibits PRC2-dependent cancer.
    Chen H; Gao S; Li J; Liu D; Sheng C; Yao C; Jiang W; Wu J; Chen S; Huang W
    Oncotarget; 2015 May; 6(15):13049-59. PubMed ID: 25944687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
    Wang D; Jiang W; Zhu F; Mao X; Agrawal S
    Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diverse, Potent, and Efficacious Inhibitors That Target the EED Subunit of the Polycomb Repressive Complex 2 Methyltransferase.
    Bagal SK; Gregson C; O' Donovan DH; Pike KG; Bloecher A; Barton P; Borodovsky A; Code E; Fillery SM; Hsu JH; Kawatkar SP; Li C; Longmire D; Nai Y; Nash SC; Pike A; Robinson J; Read JA; Rawlins PB; Shen M; Tang J; Wang P; Woods H; Williamson B
    J Med Chem; 2021 Dec; 64(23):17146-17183. PubMed ID: 34807608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PRC2 represses transcribed genes on the imprinted inactive X chromosome in mice.
    Maclary E; Hinten M; Harris C; Sethuraman S; Gayen S; Kalantry S
    Genome Biol; 2017 May; 18(1):82. PubMed ID: 28468635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
    Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
    Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 27. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.
    Turner AW; Dronamraju R; Potjewyd F; James KS; Winecoff DK; Kirchherr JL; Archin NM; Browne EP; Strahl BD; Margolis DM; James LI
    ACS Infect Dis; 2020 Jul; 6(7):1719-1733. PubMed ID: 32347704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8
    Gray SM; Amezquita RA; Guan T; Kleinstein SH; Kaech SM
    Immunity; 2017 Apr; 46(4):596-608. PubMed ID: 28410989
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting CCR8 Induces Protective Antitumor Immunity and Enhances Vaccine-Induced Responses in Colon Cancer.
    Villarreal DO; L'Huillier A; Armington S; Mottershead C; Filippova EV; Coder BD; Petit RG; Princiotta MF
    Cancer Res; 2018 Sep; 78(18):5340-5348. PubMed ID: 30026324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structure-Guided Development of Small-Molecule PRC2 Inhibitors Targeting EZH2-EED Interaction.
    Du D; Xu D; Zhu L; Stazi G; Zwergel C; Liu Y; Luo Z; Li Y; Zhang Y; Zhu K; Ding Y; Liu J; Fan S; Zhao K; Zhang N; Kong X; Jiang H; Chen K; Zhao K; Valente S; Min J; Duan W; Luo C
    J Med Chem; 2021 Jun; 64(12):8194-8207. PubMed ID: 34077206
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma.
    Natsume A; Ito M; Katsushima K; Ohka F; Hatanaka A; Shinjo K; Sato S; Takahashi S; Ishikawa Y; Takeuchi I; Shimogawa H; Uesugi M; Okano H; Kim SU; Wakabayashi T; Issa JP; Sekido Y; Kondo Y
    Cancer Res; 2013 Jul; 73(14):4559-70. PubMed ID: 23720055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age-Related Increase of EED Expression in Early Hematopoietic Progenitor Cells is Associated with Global Increase of the Histone Modification H3K27me3.
    Graffmann N; Brands J; Görgens A; Vitoriano da Conceição Castro S; Santourlidis S; Reckert A; Michele I; Ritz-Timme S; Fischer JC; Adjaye J; Kögler G; Giebel B; Uhrberg M
    Stem Cells Dev; 2015 Sep; 24(17):2018-31. PubMed ID: 25961873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PRC2.1 and PRC2.2 Synergize to Coordinate H3K27 Trimethylation.
    Healy E; Mucha M; Glancy E; Fitzpatrick DJ; Conway E; Neikes HK; Monger C; Van Mierlo G; Baltissen MP; Koseki Y; Vermeulen M; Koseki H; Bracken AP
    Mol Cell; 2019 Nov; 76(3):437-452.e6. PubMed ID: 31521505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
    Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of the polycomb repressive complex pathway in T and NK cell lymphoma: biological and prognostic implications.
    Kim SH; Yang WI; Min YH; Ko YH; Yoon SO
    Tumour Biol; 2016 Feb; 37(2):2037-47. PubMed ID: 26337274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PALI1 facilitates DNA and nucleosome binding by PRC2 and triggers an allosteric activation of catalysis.
    Zhang Q; Agius SC; Flanigan SF; Uckelmann M; Levina V; Owen BM; Davidovich C
    Nat Commun; 2021 Jul; 12(1):4592. PubMed ID: 34321472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
    Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
    ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
    Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
    Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Split luciferase-based biosensors for characterizing EED binders.
    Li L; Feng L; Shi M; Zeng J; Chen Z; Zhong L; Huang L; Guo W; Huang Y; Qi W; Lu C; Li E; Zhao K; Gu J
    Anal Biochem; 2017 Apr; 522():37-45. PubMed ID: 28111304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polycomb Repressive Complex 2 is essential for development and maintenance of a functional TEC compartment.
    Singarapu N; Ma K; Reeh KAG; Shen J; Lancaster JN; Yi S; Xie H; Orkin SH; Manley NR; Ehrlich LIR; Jiang N; Richie ER
    Sci Rep; 2018 Sep; 8(1):14335. PubMed ID: 30254371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.